BRAF and mismatch repair cancer syndrome 1: Nevertheless, a very limited number of molecular alterations gained relevance in the routine clinical settings for mCRC, beside RAS/BRAF mutations, and more recently MMR deficiency that predicts a positive response to the immune checkpoint inhibitor pembrolizumab [31].